The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

norgestrel     13-ethyl-17-ethynyl-17- hydroxy-1,2,6,7,8,9...

Synonyms: AGN-PC-00S783, CHEBI:7630, AG-E-45605, ANW-41269, AC-6144, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of norgestrel


High impact information on norgestrel


Chemical compound and disease context of norgestrel


Biological context of norgestrel


Anatomical context of norgestrel


Associations of norgestrel with other chemical compounds


Gene context of norgestrel

  • Progesterone, the parent of norgestrel, shared the latter's suppressive activity for gamma-glutamyltransferase and alkaline phosphatase biosynthesis, and behaved like its derivative towards the other enzymes [26].
  • Some biological and biochemical effects (i.e. KPI, cervical mucus, SHBG and ceruloplasmin) as well as serum ethynylestradiol and serum norgestrel, following the use of two oral contraceptives containing the same amount of norgestrel (dl-norgestrel 0.5 mg) and either 30 microgram or 50 microgram of ethynylestradiol were compared [27].
  • Norgestrel-stimulated T47D mice showed significantly more PSA in the tumors compared to tumors of the control mice [28].
  • Norgestrel reduced TeBG binding capacity but not CBG binding capacity [29].
  • In contrast to the findings of the previous study, norgestrel lowered LDL and produced less substantial decreases in HDL and HDL2 [30].

Analytical, diagnostic and therapeutic context of norgestrel


  1. Comparative effects of progesterone, norgestrel, norethisterone and tamoxifen on the abnormal uterus of the anovulatory rat. White, J.O., Moore, P.A., Marr, W., Elder, M.G., Lim, L. Biochem. J. (1982) [Pubmed]
  2. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Catherino, W.H., Jeng, M.H., Jordan, V.C. Br. J. Cancer (1993) [Pubmed]
  3. Evaluation of genotoxic potential of synthetic progestins-norethindrone and norgestrel in human lymphocytes in vitro. Ahmad, M.E., Shadab, G.G., Azfer, M.A., Afzal, M. Mutat. Res. (2001) [Pubmed]
  4. Progesterone-induced urticaria: response to buserelin. Yee, K.C., Cunliffe, W.J. Br. J. Dermatol. (1994) [Pubmed]
  5. Prospective studies of carbohydrate metabolism in "normal" women using norgestrel for eighteen months. Spellacy, W.N., Buhi, W.C., Birk, S.A. Fertil. Steril. (1981) [Pubmed]
  6. Use of low-dose oral contraceptives and stroke in young women. Schwartz, S.M., Siscovick, D.S., Longstreth, W.T., Psaty, B.M., Beverly, R.K., Raghunathan, T.E., Lin, D., Koepsell, T.D. Ann. Intern. Med. (1997) [Pubmed]
  7. Potential scope of action of tissue kallikreins in CNS immune-mediated disease. Scarisbrick, I.A., Blaber, S.I., Tingling, J.T., Rodriguez, M., Blaber, M., Christophi, G.P. J. Neuroimmunol. (2006) [Pubmed]
  8. Bone density changes during two years treatment with tibolone or conjugated estrogens and norgestrel, compared with untreated controls in postmenopausal women. Milner, M., Harrison, R.F., Gilligan, E., Kelly, A. Menopause (New York, N.Y.) (2000) [Pubmed]
  9. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Belle, D.J., Callaghan, J.T., Gorski, J.C., Maya, J.F., Mousa, O., Wrighton, S.A., Hall, S.D. British journal of clinical pharmacology. (2002) [Pubmed]
  10. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. Corson, S.L. Am. J. Obstet. Gynecol. (1994) [Pubmed]
  11. Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activity. Takahashi, M., Luu-The, V., Labrie, F. J. Steroid Biochem. Mol. Biol. (1990) [Pubmed]
  12. New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Modena, M.G., Sismondi, P., Mueck, A.O., Kuttenn, F., Lignières, B., Verhaeghe, J., Foidart, J.M., Caufriez, A., Genazzani, A.R. Maturitas. (2005) [Pubmed]
  13. Oral contraceptives and venous thromboembolism: an epidemiological review. Lidegaard, O. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception. (1996) [Pubmed]
  14. The effects of norgestrel on carbohydrate and lipid metabolism over one year. Spellacy, W.N., Buhi, W.C., Birk, S.A. Am. J. Obstet. Gynecol. (1976) [Pubmed]
  15. Biodegradable polylactate as a steroid-releasing polymer: intrauterine administration of d-norgestrel. Nilsson, C.G., Johansson, E.D., Jackanicz, T.M., Luukkainen, T. Am. J. Obstet. Gynecol. (1975) [Pubmed]
  16. Preliminary results of the endometrial and ovarian response to luteal phase norgestrel. Roland, M. Fertil. Steril. (1976) [Pubmed]
  17. Metabolism of the oral contraceptive steroids ethynylestradiol and norgestimate by normal (Huma 7) and malignant (MCF-7 and ZR-75-1) human breast cells in culture. Wild, M.J., Rudland, P.S., Back, D.J. J. Steroid Biochem. Mol. Biol. (1991) [Pubmed]
  18. The effect of steroid hormones on motility and selective migration of X- and Y-bearing human spermatozoa. Beck, K.J., Herschel, S., Hungershöfer, R., Schwinger, E. Fertil. Steril. (1976) [Pubmed]
  19. Characterization of progesterone receptor in human uterine cytosol with a synthetic progestin, norgestrel [proceedings]. Srivastava, A.K., Habib, F.K., Hancock, K.W., Stitch, S.R. J. Endocrinol. (1978) [Pubmed]
  20. Low-level, progestogen-releasing vaginal contraceptive devices. Burton, F.G., Skiens, W.E., Duncan, G.W. Contraception. (1979) [Pubmed]
  21. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Miller, L., Notter, K.M. Obstetrics and gynecology. (2001) [Pubmed]
  22. Changes in unbound sex steroids and sex hormone binding globulin--binding capacity during oral and vaginal progestogen administration. Granger, L.R., Roy, S., Mishell, D.R. Am. J. Obstet. Gynecol. (1982) [Pubmed]
  23. Simultaneous quantitative determination of norgestrel and progesterone in human serum by high-performance liquid chromatography-tandem mass spectrometry with atmospheric pressure chemical ionization. Wu, Z., Zhang, C., Yang, C., Zhang, X., Wu, E. The Analyst. (2000) [Pubmed]
  24. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. Spellacy, W.N. Am. J. Obstet. Gynecol. (1982) [Pubmed]
  25. Effects of ABT-761, a novel 5-lipoxygenase inhibitor, on the pharmacokinetics of a single dose of ethinyl estradiol and levonorgestrel in healthy female volunteers. Wong, S.L., O'Dea, R.F., Dube, L.M., Awni, W.M. Journal of clinical pharmacology. (1998) [Pubmed]
  26. Changes of activities of some transferases, alkaline phosphatase and cholinesterase in the blood of women using oral contraceptives and in vitro influence of these agents on tissular enzyme levels in rat liver. Calić, R., Straus, B., Cepelak, I. Zeitschrift für medizinische Laboratoriumsdiagnostik. (1989) [Pubmed]
  27. Some estrogenic effects of two oral contraceptives consisting of norgestrel and two different doses of ethynylestradiol. Miller, J.F., Fotherby, K., Bye, P.G., Elstein, M. Contraception. (1979) [Pubmed]
  28. Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. Kogan, I., Ballinger, J.R., Redshaw, R., Diamandis, E.P., Melegos, D.N., Kuba, R.M., Rauth, A.M. Breast Cancer Res. Treat. (1998) [Pubmed]
  29. Effects of norgestrel and metyrapone on pituitary-adrenal-ovarian function. Givens, J.R., Andersen, R.N., Ragland, J.B., Umstot, E.S. Obstetrics and gynecology. (1976) [Pubmed]
  30. The varying effects of progestins on lipid levels and cardiovascular disease. La Rosa, J.C. Am. J. Obstet. Gynecol. (1988) [Pubmed]
  31. Effect of temperature on separation of norgestrel enantiomers by high-performance liquid chromatography. Lamparczyk, H., Zarzycki, P.K., Nowakowska, J. Journal of chromatography. A. (1994) [Pubmed]
  32. Oral contraceptives and coronary artery atherosclerosis of cynomolgus monkeys. Clarkson, T.B., Shively, C.A., Morgan, T.M., Koritnik, D.R., Adams, M.R., Kaplan, J.R. Obstetrics and gynecology. (1990) [Pubmed]
  33. Hormone-releasing silicone-rubber intrauterine contraceptive devices. Effect of incorporation of various compounds on intrauterine contraceptive devices in rats. Doyle, L.L. Am. J. Obstet. Gynecol. (1975) [Pubmed]
  34. Quantitative approach for the screening of cyclodextrins by nuclear magnetic resonance spectroscopy in support of chiral separations in liquid chromatography and capillary electrophoresis enantioseparation of norgestrel with alpha-, beta- and gamma-cyclodextrins. Tárkányi, G. Journal of chromatography. A. (2002) [Pubmed]
WikiGenes - Universities